Hero Mask
Hero Mask

NEWS

Discover how Chroma is expanding our impact.

IN THE NEWS
Epigenome Editing Companies Mark Preclinical Progress
IN THE NEWS
30 biotech startups making waves
PRESS RELEASES
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement To Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Brisbane, California, and Boston, Massachusetts, JULY 20, 2023 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deploying them to address numerous therapeutically relevant targets.  Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by…
IN THE NEWS
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications